C. Feldman (Johannesburg, South Africa), A. Bossink (Bilthoven, Netherlands)
Radiographic resolution of community acquired pneumonia in elderly I. Djordjevic, T. Pejcic, M. Radovic, S. Golubovic, T. Radjenovic-Petkovic, D. Dacic (Nis, Serbia And Montenegro)
| |
Prognosis value of initial C-reactive protein (CRP) assay in patients with community acquired pneumonia K. Bouzid, O. N. S. Zouch, S. Azzabi, A. Mohsni, M. A. Baccar, B. Dhahri, L. Gharbi, H. Aouina, H. Bouacha, J. Abdelmoula (Tunis, Tunisia)
| |
Delivery of care to adult patients with community acquired pneumonia (CAP) in Russia: experience with quality indicators (QIs) I. Leshchenko, S. Ratchina, E. Shal, E. Bochanova, Y. Burdinskaya, A. Zhestkov, P. Zubeev, G. Ignatova, V. Kuzin, N. Menkov, L. Mozhina, I. Nedorozenyk, E. Ortenberg, S. Palyutin, O. Reshetko, S. Suleymanov (N. Novgorod, Smolensk, Krasnoyarsk, Samara, Che
| |
Retrospective analysis of aspiration pneumonia cases A. Fidan, M. Tokmak, G. Sarac, N. Kiral, B. Salepci, B. Caglayan (Istanbul, Turkey)
| |
Nosocomial superinfection is one of the principal cause of mortality in severe community-acquired pneumonia O. V. Fesenko (Moscow, Russian Federation)
| |
Fatal pneumomediastinum complicating cytomegalo virus pneumonia in a patient with autoimmune haemolytic anaemia S. Farag, H. Goubran (Cairo, Egypt)
| |
Retrospective study of 41 lung abscess S. Ben Saad, L. El Fekih, N. Khedher, S. Fenniche, L. Megdiche (Ariana, Tunisia)
| |
Primary lung abscess: last ten years experience in a third level hospital A. Pallares-Sanmartin, A. Cobas, A. Mendez, M. Botana, A. Fernandez-Villar, C. Represas, L. Piñeiro (Vigo, Spain)
| |
Initial evaluation and diagnostics in pleural empyema S. R. Hansen, C. N. Meyer, J. Nielsen, A. Friis-Moller (Roskilde, Hvidovre, Denmark)
| |
Comparing pleural fluid cholesterol and lactate dehydrogenase (Costa‘s criteria) and Light‘s criteria in separating exudates and transudates J. Sanico-Soliano, M. Jorge (Manila, Philippines)
| |
The implication of C-reactive protein in differentiation of various pleural effusion etiologies K. Najafizadeh, M. Zohreh, G. Fariba, S. Masoud, F. Banafshe, S. S. Mohsenian, S. Nadi, A. Shabahang Saber Tehrani (Tehran, Islamic Republic Of Iran)
| |
Empyema in old and young patients M. Merino, I. Alfageme, N. Reyes, J. Perez, J. Lima (Seville, Spain)
| |
Pleural effusion predicts poor outcomes in hospitalized patients with community-acquired pneumonia: results from the CAPO international cohort study M. Mirsaeidi, J. Portillo, E. Anaya, P. Peyrani, J. Guardiola, F. Arnold, R. Nakamatsu, C. Victorio, G. Aiello, M. Perez Mirabal, J. Ramirez, The CAPO Investigators (Louisville, KY, United States Of America; Concepcion del Uruguay, Entre Rios, Argentina;
| |
Outcome and medical and surgical treatment in pleural empyema J. Nielsen, C. N. Meyer, S. R. Hansen, A. Friis-Møller (Roskilde, Hvidovre, Denmark)
| |
Anti-endotoxin humoral immunity in patients with pneumonia V. Beloglazov, P. Radzivuil, A. Gordienko, K. Byeloglazova, I. DuBuske, L. DuBuske (Simferopol, Ukraine; Gardner, MA, United States Of America)
| |
Evolution of serotype coverages of 23- and 7-valent pneumococcal vacciness for S. pneumonia isolates from Spanish middle age and older adults with pneumonia, 2002-2007 A. Vila-Corcoles, M. M. Juarez-Laiz, I. Guinea-Oruechevarria, E. Salsench-Serrano, C. DeDiego-Cabanes, F. Bejarano-Romero (Tarragona, Spain)
| |
Clinical effectiveness of pneumococcal vaccination against nonbacteremic pneumonia in people over 50 years A. Vila-Corcoles, I. Hospital-Guardiola, T. Rodriguez-Blanco, O. Ochoa-Gondar, M. M. Juarez-Laiz, Study Group EVAN-50 (Tarragona, Barcelona, Spain)
| |
Influenza and pneumoccocal vaccination protect against all cause mortality in COPD S. Schembri, S. Morant, J. Winter, T. MacDonald (Dundee, United Kingdom)
| |
Safety and immunogenicity of a dose-sparing, trivalent inactivated seasonal influenza vaccine containing an advax adjuvant – a phase 1/2 randomised controlled trial D. Sajkov, D. Gordon, N. Petrovsky (Bedford Park, Adelaide/SA, Australia)
| |